Pharmacologic modulation of TNF production by endotoxin stimulated macrophages:In vitro andin vivo effects of auranofin and other chrysotherapeutic compounds

M. Chaffman, R. N. Brogden, R. C. Heel, T. M. Speight and G. S. Avery,Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis. Drugs27, 378–424 (1984).

A. J. Lewis, and D. T. Walz,Immunopharmacology of gold. Prog. in Medicinal Chem.19, 1–58 (1982).

N. Hanna, M. J. Di Martino, D. E. Griswold and G. Poste,Immunology of Auranofin — An overview. Proc. of Smith Kline Internatl. Sypos. 60–70 (1982).

D. T. Walz, M. J. Di Martino, B. Sutton and A. Misher,SK&F 36914 — An agent for oral chrysotherapy. J. Pharm. Exp. Ther.181, 292–297 (1972).

D. T. Walz, M. J. Di Martino, L. W. Charkrin, B. M. Sutton and A. Misher,Antiarthritic properties and unique pharmacologic profile of a potential chrysotherapeutic agent: SK&F D-39162. J. Pharm. Exp. Ther.191, 142–152 (1976).

L. M. DeYoung, D. A. Spires, J. Kheifets, and T. G. Terrell,Biology and pharmacology of recombinant human interleukin-β induced rat ear inflammation. Agents and Actions21, 325–327 (1987).

D. T. Walz, M. J. DiMartino and D. E. Griswold,Comparative pharmacology and biological effects of different gold compounds. J. Rheumatol.9 (Suppl. 8), 54–60 (1982).

R. M. Snyder, C. K. Mirabelli and S. T. Crooke,Cellular association, intracellular distribution, and efflux of auranofin via sequential ligand exchange reactions. Biochem. Pharmacol.35, 923–932 (1986).

R. M. Snyder, C. K. Mirabelli and S. T. Crooke,Cellular interactions of auranofin and a related gold complex with RAW 264.7 macrophages. Biochem. Pharmacol.36, 647–654 (1987).

E. R. Unanue and P. M. Allen,The basis for the immunoregulatory role of macrophages and other accessory cells. Science236, 551–557 (1987).

C. F. Nathan,Secretory products of macrophages. J. Clin. Invest.79, 319–326 (1987).

D. O. Adams and T. A. Hamilton,The cell biology of macrophage activation. Ann. Rev. Immunol.2, 283–318 (1984).

M. A. Scheinberg, L. Santos and A. Finkelstein,The effect of auranofin and sodium aurothiomalate on peripheral blood monocytes. J. Rheumatol.9, (3), 366–369 (1982).

M. L. Barrett and G. P. Lewis,Unique properties of auranofin as a potential anti-rheumatic drug. Agents and Actions19, 109–115 (1986).

J. C. Lee, M. J. Di Martino, B. J. Votta and N. Hanna,Effect of auranofin treatment on aberrant splenic interleukin production in adjuvant rats. J. Immunol.139, 3268–3274 (1987).

D. E. Griswold, J. C. Lee, G. Poste and N. Hanna,Modulation of macrophage-lymphocyte interactions by the antiarthritic gold compound, auranofin. J. Rheumatol.12, 490–497 (1985).

D. A. Flick and G. E. Gifford,Comparison of in vitro cytotoxic assays for tumor necrosis factor. J. Immunol. Methods68, 167–175 (1984).

N. L. Gottlieb,Pharmacology of Auranofin: Overview and Update. Scans. J. Rheumatol.63, 19–28 (1986).

R. J. Coughlan, M. B. Richter and G. S., Panayi, Changes in mononuclear cell function in patients with rheumatoid arthritis following treatment with auranofin. Clin. Rheumatol.3, Supp. 25–32 (1984).

K. J. Tracey, Y. Fong, D. G. Hesse, K. R. Manogue, A. T. Lee, G. C. Kuo, S. F. Lowry and A. Cerami,Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature330, 662–664 (1987).

S. W. Lee, A.-P. Tsou, H. Chan, J. Thomas, K. Petrie, E. M. Eugui and A. C. Allison,Glucocorticoids selectively inhibit the transcription of the interleukin 1-β gene and decrease the stability of interleukin 1-β mRNA. Proc. Nat. Acad. Sci. USA85, 1204–1208 (1988).

B. Beutler and A. Cerami,Cachectin: More than a tumor necrosis factor. New England J. Med.316, 379–385 (1987).